ZyVersa Therapeutics announces publication on inflammasome ASC
PremiumThe FlyZyVersa Therapeutics announces publication on inflammasome ASC
2M ago
ZyVersa Therapeutics expects cas to fund requirements on month-to-month basis
Premium
The Fly
ZyVersa Therapeutics expects cas to fund requirements on month-to-month basis
5M ago
ZyVersa Therapeutics reports Q1 EPS ($4.53) vs. ($135.88) last year
Premium
The Fly
ZyVersa Therapeutics reports Q1 EPS ($4.53) vs. ($135.88) last year
5M ago
ZyVersa Therapeutics highlights publication on NLRP3 inflammasome inhibition
PremiumThe FlyZyVersa Therapeutics highlights publication on NLRP3 inflammasome inhibition
6M ago
Zyversa Therapeutics’ 1-for-35 Reverse Split: Navigating the Risks to Shareholder Value and Liquidity
Premium
Company Announcements
Zyversa Therapeutics’ 1-for-35 Reverse Split: Navigating the Risks to Shareholder Value and Liquidity
6M ago
ZyVersa Therapeutics expects cas to fund requirements on month-to-month basis
Premium
The Fly
ZyVersa Therapeutics expects cas to fund requirements on month-to-month basis
6M ago
ZyVersa data adds evidence of NLRP3 focus in obesity, says Piper Sandler
PremiumThe FlyZyVersa data adds evidence of NLRP3 focus in obesity, says Piper Sandler
7M ago
ZyVersa publishes white paper detailing tole of inflammasomes, ASC specks
Premium
The Fly
ZyVersa publishes white paper detailing tole of inflammasomes, ASC specks
7M ago
ZyVersa Therapeutics highlights publication on inflammasome activation
Premium
The Fly
ZyVersa Therapeutics highlights publication on inflammasome activation
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100